Neoadjuvant treatment of pancreatic ductal adenocarcinoma
- 10.08.2022
- short review
Erschienen in:
- Verfasst von
- Katharina Kosma
- Sabine Thalhammer
- Thomas Gruenberger
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 3/2022
Summary
Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer is the subject of several ongoing randomized controlled trials (RCTs). Retrospective studies and completed RCTs favor the use of neoadjuvant therapy in pancreatic cancer. Yet, the optimal chemotherapy regimen has not been defined. The objective of this report is to provide a review of currently available study data of neoadjuvant therapy in pancreatic cancer.
Anzeige
- Titel
- Neoadjuvant treatment of pancreatic ductal adenocarcinoma
- Verfasst von
-
Katharina Kosma
Sabine Thalhammer
Thomas Gruenberger
- Publikationsdatum
- 10.08.2022
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-022-00832-7
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.